A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2011
11/03/2011	US20110269686 Cxcr4 antagonist and use thereof
11/03/2011	US20110269683 Receptor(sstr2)-selective somatostatin antagonists
11/03/2011	US20110269674 Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses
11/03/2011	US20110269668 Fused Heteroaryl Diamide Compounds Useful as MMP-13 Inhibitors
11/03/2011	US20110269146 Expression Vectors and Cell Lines Expressing Vascular Endothelial Growth Factor D, and Method of Treating Melanomas
11/03/2011	US20110268970 Mesoporous nanoparticles
11/03/2011	US20110268825 Compositions that include anthocyanidins and methods of use
11/03/2011	US20110268803 Lung targeting dual drug delivery system
11/03/2011	US20110268791 Porous nanoparticle supported lipid bilayer nanostructures
11/03/2011	US20110268774 preparation of stem cells with reprogrammed cell signalling, a method of producing the preparation and a method of use thereof
11/03/2011	US20110268771 Chewable gelled emulsions
11/03/2011	US20110268769 Drug delivery vehicle for cancer therapy, process for producing the same, and pharmaceutical preparation using the same
11/03/2011	US20110268767 Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses
11/03/2011	US20110268766 Engineered Cells Expressing Multiple Immunomodulators And Uses Thereof
11/03/2011	US20110268761 Effective Sensitizing Dose of a Gelled Immunomodulating Topical Composition
11/03/2011	US20110268754 Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
11/03/2011	US20110268751 Weekly Dosing Regimens for Anti-CD30 VC-PAB-MMAE Antibody Drug-Conjugates
11/03/2011	US20110268750 Chimeric polynucleotides and polypeptides enabling secretion of a polypeptide of interest in association with exosomes and use thereof for the production of immunogenic compositions
11/03/2011	US20110268749 Treatment of cancer via targeting of il-13 receptor-alpha2
11/03/2011	US20110268735 Multimeric constructs
11/03/2011	US20110268733 ANTI-Siglec-15 ANTIBODY
11/03/2011	US20110268726 Anti-CD38 human antibodies and uses thereof
11/03/2011	US20110268724 Methods and materials relating to cd84-like polypeptides and polynucleotides
11/03/2011	US20110268722 Combination therapies with mitochondrial-targeted anti-tumor agents
11/03/2011	US20110268720 Formulations of 5-fluorocytosine and uses thereof
11/03/2011	US20110268719 Annatto Extract Compositions, Including Geranyl Geraniols And Methods Of Use
11/03/2011	US20110268714 CD34 Stem Cell-Related Methods and Compositions
11/03/2011	US20110268709 Generation of Histocompatible Tissues Using Nuclear Transplantation
11/03/2011	US20110268695 Use of hmgb fragments as anti-inflammatory agents
11/03/2011	US20110268694 Methods for treating vascular leak syndrome
11/03/2011	US20110268678 Vitamin d forming sunscreen
11/03/2011	US20110268666 Novel gastroretentive delivery system
11/03/2011	US20110268659 High shear application in drug delivery
11/03/2011	US20110268658 Polymer-agent conjugates, particles, compositions, and related methods of use
11/03/2011	US20110268657 Compositions and methods for the treatment of tumor of hematopoietic origin
11/03/2011	US20110268656 J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
11/03/2011	US20110268655 Anti-alpha v immunoliposome compositions, methods and uses
11/03/2011	DE102010019099A1 Ausgewählte Pflanzenextrakte zur Behandlung von Entzündungserkrankungen Selected plant extracts for the treatment of inflammatory diseases
11/03/2011	CA2803254A1 Slit and roundabount (robo) mediated lymph vessel formation and uses thereof
11/03/2011	CA2800818A1 Cationic lipid
11/03/2011	CA2800569A1 Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities
11/03/2011	CA2797808A1 Piperazinotriazines as pi3k inhibitors for use in the treatment of antiproliferative disorders
11/03/2011	CA2797772A1 Pyrazole compounds as jak inhibitors
11/03/2011	CA2797719A1 Small molecule inhibitors of usp1 deubiquitinating enzyme activity
11/03/2011	CA2795799A1 Anti-erbb3 antibodies
11/03/2011	CA2795559A1 Crystalline peptide epoxyketone immunoproteasome inhibitor
11/03/2011	CA2795275A1 Lyophilized formulation of pectin-adriamycin conjugate and preparation method thereof
11/02/2011	EP2383291A2 Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto
11/02/2011	EP2383290A2 Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto
11/02/2011	EP2383288A2 Differential in tumour gene products and use of same
11/02/2011	EP2383282A1 Peptides for treatment of the human papillomavirus (HPV)-associated cancer and other epithelial tumors
11/02/2011	EP2383268A1 Pyrazolylaminopyridine derivatives useful as kinase inhibitors
11/02/2011	EP2382995A2 Ligand conjugates of Vinca alkaloids, analogs and derivatives
11/02/2011	EP2382993A1 Combination of drugs with protein-binding prodrugs
11/02/2011	EP2382977A1 Therapeutic agents targeting the ncca-atp channel and methods of use thereof
11/02/2011	EP2382976A1 Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
11/02/2011	EP2382974A1 Use of cyclosquaramide compounds as anti-tumour agents
11/02/2011	EP2382314A1 C1orf59 peptides and vaccines including the same
11/02/2011	EP2382238A1 Anti-lymphotoxin antibodies
11/02/2011	EP2382214A1 Method of preparing (+)-1,4-dihydro-7-ý(3s,4s)-3methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
11/02/2011	EP2382210A2 Pyrimidinediamine kinase inhibitors
11/02/2011	EP2382207A2 Pi3k/mtor kinase inhibitors
11/02/2011	EP2382193A1 Ppar agonist compositions and methods of use
11/02/2011	EP2382190A1 Toluidine sulfonamides and their use as-inhibitors
11/02/2011	EP2382189A1 Toluidine sulfonamides and their use
11/02/2011	EP2381963A2 A medical device loaded with formulations for targeted delivery of biologically active material/s and method of manufacture thereof
11/02/2011	EP2381950A2 Compositions and methods of use
11/02/2011	EP2381949A1 Immunostimulating saponins for use in in situ tumor-destruction therapy
11/02/2011	EP2381943A1 Substituted quinazoline compounds
11/02/2011	EP2381942A1 Combination therapies for neoplastic disorders
11/02/2011	EP2381780A1 Compositions comprising decitabine and tetrahydrouridine and uses thereof
11/02/2011	EP2381779A1 Selective inhibitors of akt and methods of using same
11/02/2011	EP2381777A1 Azaindole derivatives as kinase inhibitors
11/02/2011	EP2381775A1 Small molecule inhibitors of necroptosis
11/02/2011	EP2278973B1 Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
11/02/2011	EP2126136B1 Diagnosis of prostate cancer
11/02/2011	EP2069354B1 Aza-benzofuranyl compounds and methods of use
11/02/2011	EP2007767B1 Pyrrolopyrimidine derivatives used as hsp90 inhibitors
11/02/2011	EP1931735B1 High-purity texaphyrin metal complexes
11/02/2011	EP1853250B1 Combinations and modes of administration of therapeutic agents and combination therapy
11/02/2011	EP1836225B1 Kir-binding agents and methods of use thereof
11/02/2011	EP1827437B1 Combinations of therapeutic agents for treating cancer
11/02/2011	EP1615952B1 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
11/02/2011	EP1461449B1 System for monitoring bacterial tumor treatment
11/02/2011	EP1425389B1 Human antibodies specific for interleukin 15 (il-15)
11/02/2011	EP1311290B1 Expression of herstatin, an alternative her-2/neu product, in cells that express either p185her-2 or the egf receptor inhibits receptor activity and cell growth
11/02/2011	EP1299522B1 Alteration of cell membrane
11/02/2011	EP1212359B1 Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein
11/02/2011	EP1100512B1 Use of thioarabinofuranosyl compounds
11/02/2011	CN102232086A Process for the modulation of the antagonistic activity of a monoclonal antibody
11/02/2011	CN102232071A Fused multicyclic compounds as protein kinase inhibitors
11/02/2011	CN102232067A Nicotinamide derivatives
11/02/2011	CN102231984A Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
11/02/2011	CN102231983A Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
11/02/2011	CN102229962A Oncolytic adenovirus vector for modifying and expressing two exogenous genes by fibrin, construction method and application of vector
11/02/2011	CN102229961A Conditionally replicating oncolytic adenoviral vector used for expressing two exogenous genes and modified by small peptide, construction method and application thereof
11/02/2011	CN102229939A Optimized high-activity human lysozyme gene as well as expression vectors and applications thereof
11/02/2011	CN102229928A Small-interfering RNA (Ribonucleic Acid) of human RBBP6 (Retinoblastoma-binding Proteingene) and application thereof
11/02/2011	CN102229671A Anti-IMMT anthropogenic Fab antibody and application thereof in preparing anti-liver cancer drugs
11/02/2011	CN102229667A Polyethylene glycol modified porcine alpha-interferon, preparation method and application thereof

1 ... 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 ... 2211